Avenue Therapeutics Announces Appointment of Ms. E. Garrett Ingram to Board of Directors
August 01 2019 - 8:00AM
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a specialty
pharmaceutical company focused on the development and
commercialization of intravenous (IV) tramadol, today announced
that Ms. Garrett Ingram has been appointed to its Board of
Directors. Ms. Ingram joined Cipla USA, Inc. (“Cipla”) in July 2019
as Chief Commercial Officer, Specialty Hospital Business, U.S. to
lead the transformation of the current and future specialty branded
platforms. She will serve as one of the three Cipla representatives
on Avenue’s Board of Directors, succeeding Mr. Nishant Saxena who
has stepped down from Avenue’s Board of Directors to become Cipla’s
Chief Executive Officer of International Business (Europe and
Emerging Markets).
“Ms. Ingram’s extensive launch and
commercialization expertise and proven track record of
distinguished leadership will be a significant asset to Avenue,”
said Dr. Lindsay Rosenwald, Avenue’s Executive Chairman. “We look
forward to working with her to maximize the value of IV
tramadol.”
“Avenue has successfully completed its Phase 3
Program for IV tramadol, which could become an important addition
in acute pain management in the U.S.,” said Ms. Ingram. “I am
excited to lend my expertise to the organization to help
successfully bring IV tramadol to the U.S. market.”
Garrett Ingram is a seasoned leader with more than
twenty years of experience in pharmaceuticals, biotech, device
strategy and marketing. Prior to her new role at Cipla, Ms. Ingram
served as Chief Marketing Officer at MannKind Corporation, based in
California. In addition, she has served in roles as Senior Vice
President, Managed Markets at Dexcom and Vice President, Head of
Market Access at Sanofi, where she had responsibility across four
of the U.S. Business Units: Diabetes & Cardiovascular, General
Medicines, Sanofi Genzyme Specialty Care, and Sanofi Pasteur from
2014 to 2016. Prior to joining Sanofi, she held the position of
Vice President of Market Access Strategy at Bristol Myers Squibb,
where she led the access, reimbursement, patient affordability and
emerging customer strategy teams across the portfolio of diabetes,
RA, cardiovascular, oncology, immunology, neuroscience and pipeline
assets. Ms. Ingram holds a Bachelor of Science degree from East
Carolina University, a Master’s Degree in public health and
community education from the University of South Carolina and has
completed multiple post graduate studies at Wharton School of
Business.
About Avenue TherapeuticsAvenue is
a specialty pharmaceutical company focused on the development and
commercialization of intravenous (IV) tramadol for the management
of moderate to moderately severe postoperative pain. IV tramadol
may fill a gap in the acute pain market between IV
acetaminophen/NSAIDs and IV conventional narcotics. Avenue has
completed its Phase 3 program of IV tramadol for the management of
postoperative pain and plans to submit a New Drug Application to
the U.S. Food and Drug Administration by year-end. Avenue is
headquartered in New York City and was founded by Fortress Biotech,
Inc. (NASDAQ: FBIO). For more information, visit
www.avenuetx.com.
Contacts: Jaclyn Jaffe and William
Begien, Investor RelationsAvenue Therapeutics, Inc.(781) 652‐4500
ir@avenuetx.com
Fortress Biotech (NASDAQ:FBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Fortress Biotech (NASDAQ:FBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024